Science & Technology
Science and Technology
Science and Technology 
Fri, March 4, 2011
TORONTO, March 4 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD), a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it will deliver a corporate presentation on March 16th, 2011 during Roth Capital Partner's 23rd Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. SQI's presentation is at 11:00 am PT.
Roth is a U.S. investment banking firm dedicated to the small-cap public market. The three-day conference attracts more than 1,000 institutional investors from around the world, and more than 400 presenting companies from the U.S., Canada and China.
About SQI Diagnostics
SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate patient results in less time, significantly reduce labour, and increase profits...All in One Drop. For more information, please visit [ www.sqidiagnostics.com ]
Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.